Plasma cell dyscrasia: monoclonal gammopathies, AL-amyloidosis, multiple myeloma Clinical case study
https://doi.org/10.17650/1818-8346-2023-18-1-57-62
Abstract
This study was performed in real clinical practice settings. Our paper describes two case studies which show the difficulty of differential diagnosis of monoclonal gammopathies, multiple myeloma associated with AL-amyloidosis and primary AL-amyloidosis.
About the Authors
V. V. Cherepanova
Municipal Clinical Hospital No. 33
Russian Federation
Russian Federation
Valentina Vasil’evna Cherepanova
603122, Nizhniy Novgorod, Lenina Prospekt, 54
M. A. Kurysheva
Municipal Clinical Hospital No. 33
Russian Federation
Russian Federation
603122, Nizhniy Novgorod, Lenina Prospekt, 54
S. V. Odintsova
Municipal Clinical Hospital No. 33
Russian Federation
Russian Federation
603122, Nizhniy Novgorod, Lenina Prospekt, 54
References
1. WHO classification of tumours of haematopoietic and lymphoid tissues. Eds.: Swerdlow S.H., Campo E., Harris N.L. et al. Revised 4<sup>th</sup> edn.
2. Haematology. National Guidance. Ed.: O.A. Rukavitsyn. Moscow: GEOTAR-Media, 2015. Pp. 550–588. (In Russ.).
3. Smirnov A.V., Afanasyev B.V., Poddubnaya I.V. et al. Monoclonal gammopathy of renal significance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment. Nefrologiya = Nephrology 2019;23(6):9–28. (In Russ.). DOI:10.36485/1561-6274-2019-23-6-9-28
4. Smirnov A.V., Dobronravov V.A., Khrabrova M.S., Afanasyev B.V. Kidney involvement in monoclonal gammopathies: multidisciplinary approach in oncohematology and nephrology. Onkogematologiya = Oncohematology 2020;15(2):49–60. (In Russ.). DOI:10.17650/1818-8346-2020-15-2-49-60
5. Rekhtina I.G., Mendeleeva L.P., Soboleva N.P. et al. Detection of paraprotein in plasma cell tumours. Terapevticheskiy arkhiv = Therapeutic Archive 2022;94(1):135–44. (In Russ.). DOI:10.26442/004036.602022.01.2013216
6. Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V. et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2020;29(1):13–24. (In Russ.). DOI:10.32756/0869-5490-2020-1-13-24
7. Zakharova E.V., Makarova T.A., Stolyarevich E.S., Vorobyova O.A. Spectrum og monoclonal gammopathies of renal significance in the real practice. Nephrologiya = Nephrology 2019;23(suppl 1):89. (In Russ.). DOI:10.36485/1561-6274-2019-23-5-89-99
8. Merlini G., Ashutosh D., Wechalekar A.D., Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121(26):5124–30. DOI:10.1182/blood-2013-01-453001
9. Gudkova A.Ya., Lapekin S.V., Bezhanishvili T.G. et al. AL-amyloidosis with cardiac involvement. Diagnostic capabilities of noninvasive methods. Terapevticheskiy arkhiv = Therapeutic Archive 2021;93(4):487–96. (In Russ.). DOI:10.26442/00403660.2021.04.200689
10. Bessmelstev S.S., Abdulkadyrov K.M. Multiple myeloma. Medical Guidance. Moscow: Spetsial’noe izdatel’stvo meditsinskikh knig, 2016. 493 p. (In Russ.).
11. Khyshova V.A., Rekhtina I.G., Firsova M.V., Mendeleeva L.P. Difficulties in diagnosis primary AL-amyloidosis. Onkogematologiya = Oncohematology 2021;16(3):74–82. (In Russ.). DOI:10.17650/1818834620211637482
12. Hamedi R., Bazarbachi A.H., Bazarbachi A. et al. Comprehensive review of AL amyloidosis: somepractical recommendations. Blood Cancer J 2021;11(5):97. DOI:10.1038/s41408-021-00486-4
13. Keren D., Bocsi G., Billman B. et al. Laboratory detection and initial diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 2022;146(5):575–90. DOI:10.5858/arpa.2020-0794-CP
14. Skvortsova N.V., Kovynev I.B., Halzov K.V., Pospelova T.I. The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice. Onkogematologiya = Oncohematology 2020;15(3):38–50. (In Russ.). DOI:10.17650/1818-8346-2020-15-3-38-50
Review
For citations:
Cherepanova V.V., Kurysheva M.A., Odintsova S.V. Plasma cell dyscrasia: monoclonal gammopathies, AL-amyloidosis, multiple myeloma Clinical case study. Oncohematology. 2023;18(1):57-62. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-1-57-62
Views:
8660
Email this article 